Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Abbott Laboratories (NYSE: ABT).

Full DD Report for ABT

You must become a subscriber to view this report.


Recent News from (NYSE: ABT)

Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter
ABBOTT PARK, Ill., May 3, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance of the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™ . Advisor HD Grid employs a new design that allows physicians to see things diff...
Source: PR Newswire
Date: May, 03 2018 09:00
My Dividend Growth Portfolio - 42 Holdings, 4 Buys
April was a much busier month than March. On the investing front, we are in the middle of earnings season. Earnings season is the quarterly time of year when investors get that inside snapshot as to how each company is operating. So far it has been quite good which in turn is why I've felt com...
Source: SeekingAlpha
Date: May, 03 2018 05:22
Abbott's XIENCE Sierra(TM) Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease
ABBOTT PARK, Ill., May 2, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that Japan's Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary st...
Source: PR Newswire
Date: May, 02 2018 09:00
Free Research Report as Intuitive Surgical's Quarterly Revenue Surged 25%; Adjusted EPS Soared 43%
Stock Monitor: Abbott Laboratories Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 01, 2018 / Active-Investors.com has just released a free earnings report on Intuitive Surgical, Inc. (NASDAQ: ISRG ). If you want access to this report all you need to do is sign up now by click...
Source: ACCESSWIRE IA
Date: May, 01 2018 07:50
Roche Drifting Without Perception-Changing Data
Once tapped as the future belle of the ball due to its deep pipeline of potential add-on/combo oncology therapies, Roche ( OTCQX:RHHBY ) has continued to lag rivals like Merck ( MRK ) as investors grow more concerned that Roche’s PD-L1 antibody Tecentriq will have trouble standing o...
Source: SeekingAlpha
Date: April, 30 2018 15:28
This Dividend Aristocrat Just Printed 40%+ EPS Growth - Is It A Buy?
By Nick McCullum At Sure Dividend, we often write about the merits of investing in the Dividend Aristocrats. In order to be a Dividend Aristocrat, a company must: Be in the S&P 500 Meet certain minimum size and liquidity requirements Have 25+ years of consecutive dividend in...
Source: SeekingAlpha
Date: April, 27 2018 11:06
Sanquin Selects Abbott's "Alinity(TM) s" Solution for Blood and Plasma Screening
LONG-TERM AGREEMENT BETWEEN SANQUIN, A LEADER IN BLOOD SERVICES, AND ABBOTT, A GLOBAL LEADER IN TRANSFUSION MEDICINE, HELPS ENSURE A SAFE AND EFFICIENT BLOOD SUPPLY IN THE NETHERLANDS AMSTERDAM , April 23, 2018 /PRNewswire/ -- Sanquin and Abbott (NYSE: ABT) announced ...
Source: PR Newswire
Date: April, 23 2018 09:00
The Passive DGI Core Portfolio: Income, Safety, And Growth
The concept of Dividend Growth Investing (or DGI) is simple and rational. DGI generally means that you invest in a set of dividend-paying stocks that grow their dividend payout year after year. If you are still in the accumulation phase, reinvest (drip) the dividends, which results in more sha...
Source: SeekingAlpha
Date: April, 21 2018 08:38
Danaher's Growing Leverage To Life Sciences Improves The Long-Term Outlook
As investors have become a little more concerned that the industrial recovery story has peaked, Danaher ’s ( DHR ) far larger skew towards health and life sciences has started looking better and better. At the risk of oversimplification, I think the greater skew toward health care/life...
Source: SeekingAlpha
Date: April, 20 2018 14:22
Abbott Extends Title Sponsorship of Abbott World Marathon Majors through 2023
LONDON , April 20, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) and the World Marathon Majors today announced the renewal of Abbott's title sponsorship. The partnership will extend into 2023, with the new four-year agreement beginning in 2019. Abbott became the first title sponsor of the ...
Source: PR Newswire
Date: April, 20 2018 10:10

 


About Abbott Laboratories (NYSE: ABT)

Logo for Abbott Laboratories (NYSE: ABT)

Not available

 

Contact Information

 

 

Current Management

  • Miles D. White / CEO
  • Robert L. Parkinson Jr. / President, COO

Current Share Structure

  • Market Cap: $107,400,282,545 - 05/11/2018
  • Issue and Outstanding: 1,753,187,766 - 03/31/2018

 


Recent Filings from (NYSE: ABT)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 22 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 08 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 29 2018

 

 


Daily Technical Chart for (NYSE: ABT)

Daily Technical Chart for (NYSE: ABT)


Stay tuned for daily updates and more on (NYSE: ABT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: ABT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ABT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of ABT and does not buy, sell, or trade any shares of ABT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/